Chemistry and Pharmacology of Anticancer Drugs 2nd Edition

Description of Chemistry and Pharmacology of Anticancer Drugs

While drug therapies developed in the last 80 years have markedly improved treatment outcomes and the management of some types of cancers, the lack of effectiveness and side effects associated with the most common treatment types remain unacceptable. However, recent technological advances are leading to improved therapies based on targeting distinct biological pathways in cancer cells. Chemistry and Pharmacology of Anticancer Drugs is a comprehensive survey of all families of anticancer agents and therapeutic approaches currently in use or in advanced stages of clinical trials, including biological-based therapies.

The book is unique in providing molecular structures for all anticancer agents, discussing them in terms of history of development, chemistry, mechanism of action, structure–function relationships, and pharmacology. It also provides relevant information on side effects, dosing, and formulation. The authors, renowned scientists in cancer research and drug discovery, also provide up-to-date information on the drug discovery process, including discussions of new research tools, tumor-targeting strategies, and fundamental concepts in the relatively new areas of precision medicine and chemoprevention.

Chemistry and Pharmacology of Anticancer Drugs is an indispensable resource for cancer researchers, medicinal chemists and other biomedical scientists involved in the development of new anticancer therapies. Its breadth of coverage, clear explanations, and illustrations also make it suitable for undergraduate and postgraduate courses in medicine, pharmacy, nursing, dentistry, nutrition, the biomedical sciences, and related disciplines.

Key Features:

• Summarizes the fundamental causes of cancer, modes of treatment, and strategies for cancer drug discovery
• Brings together a broad spectrum of information relating to the chemistry and pharmacology of all families of anticancer agents and therapies
• Includes up-to-date information on cutting-edge aspects of cancer treatments such as biomarkers, pharmacogenetics, and pharmacogenomics
• Features new chapters on the “Evolution of Anticancer Therapies”, “Antibody-Based Therapies”, and “Cancer Chemoprevention”

About the Author

David Thurston is Emeritus Professor of Drug Discovery in the Institute of Pharmaceutical Science (IPS) at King’s College London. He has a first degree in pharmacy, an MSc in Precision Medicine and a PhD in synthetic medicinal chemistry, and has worked at two schools of pharmacy in the USA (University of Texas at Austin and Kentucky Colleges of Pharmacy) and four in the UK (the Portsmouth, Nottingham, London University and King’s College School of Pharmacy).

Ilona Pysz has a first degree in Forensic Science, an MSc in Cancer Pharmacology and a PhD in Pharmaceutical Science in which she produced a number of novel Antibody-Drug Conjugates (ADCs), and developed a hydrophobicity assay which allows the physico-chemical properties of ADC payloads to be evaluated and compared.

Read more about: David E. Thurston, Ilona Pysz